PETVIVO HOLDINGS, INC. TO ANNOUNCE SECOND QUARTER 2022 RESULTS
November 11 2021 - 3:30PM
PetVivo Holdings, Inc. (“PetVivo”), an emerging biomedical device
company focused on the commercialization of innovative medical
therapeutics for animals, will release financial results for the
second fiscal year quarter 2022 on Monday, November 15, 2021 after
market close. The company will host a Q&A conference call to
discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same
day.
A live webcast of the conference call and related
earnings release materials can be accessed on PetVivo’s Investor
Relations website at https://audience.mysequire.com/webinar-view?webinar_id=94479447-ec7e-4888-a1cb-a27d9eae93fd.
A replay of the webcast will be available through the same link
following the conference call.
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for animals. The Company's
strategy is to leverage human therapies for the treatment of dogs
and horses in a capital and time efficient way. A key component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™, a
veterinarian-administered, intraarticular injection for the
treatment of osteoarthritis in dogs and horses, is scheduled for
expanded commercial sale in the fourth quarter of this year.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Apr 2024 to May 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From May 2023 to May 2024